Stock ITCI INTRA-CELLULAR THERAPIES, INC.
Add to a list
Suspension of trading

Intra-Cellular Therapies, Inc. Stock

Stocks

ITCI

US46116X1019

Pharmaceuticals

Delayed Nasdaq
Other stock markets
 04:00:00 02/04/2025 HKT 		5-day change 1st Jan Change
131.87 USD -0.04% Intraday chart for Intra-Cellular Therapies, Inc. -.--% -
15/04/25 J&J Boosts Outlook Despite Incoming Tariff Costs -- Update DJ
15/04/25 J&J Increases Outlook After Beating 1Q Expectations DJ

Valuation: Intra-Cellular Therapies, Inc.

Market Cap 14.02B 12.14B 11.32B 10.41B 19.66B 1,333B 19.88B 133B 52.21B 667B 52.66B 51.5B 2,209B P/E 2023
-49.2x
P/E 2024 -115x
Enterprise Value 13.04B 11.29B 10.53B 9.68B 18.28B 1,240B 18.48B 124B 48.55B 620B 48.97B 47.89B 2,054B EV / Sales 2023
13.8x
EV / Sales 2024 11.6x
Free-Float
95.68%
Yield 2023 *
-
Yield 2024 -
* Estimated data More valuation ratios

Latest news : Intra-Cellular Therapies, Inc.

15/04/25 J&J Boosts Outlook Despite Incoming Tariff Costs -- Update DJ
15/04/25 J&J Increases Outlook After Beating 1Q Expectations DJ
15/04/25 Intra-Cellular Therapies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
03/04/25 Intra-Cellular Therapies, Inc.(NasdaqGS:ITCI) dropped from S&P Pharmaceuticals Select Industry Index CI
03/04/25 Intra-Cellular Therapies, Inc.(NasdaqGS:ITCI) dropped from S&P TMI Index CI
03/04/25 Intra-Cellular Therapies, Inc.(NasdaqGS:ITCI) dropped from S&P Global BMI Index CI
02/04/25 Johnson & Johnson Completes Intra-Cellular Therapies Purchase MT
02/04/25 J&J: about to acquire Intra-Cellular Therapies Zonebourse
02/04/25 Johnson & Johnson Expects Lower Earnings Impact From Intra-Cellular Therapies Acquisition MT
02/04/25 Intra-Cellular Therapies, Inc.(NasdaqGS:ITCI) dropped from NASDAQ Composite Index CI
02/04/25 Johnson & Johnson Innovative Medicine completed the acquisition of Intra-Cellular Therapies, Inc. from a group of shareholders. CI
02/04/25 Johnson & Johnson Expects Lower EPS Impact From Intra-Cellular Deal MT
02/04/25 Johnson & Johnson Announces Expected Closing Date For Intra-Cellular Acquisition RE
More news

Analysts' recommendations: Intra-Cellular Therapies, Inc.

25/02/25 Analyst recommendations: Block, Lucid, Celsius, Dun & Bradstreet, Sentinelone... Zonebourse
24/02/25 Mizuho Downgrades Intra-Cellular Therapies to Neutral From Outperform, Lowers Price Target to $132 From $140 MT
05/02/25 UBS Adjusts Price Target on Intra-Cellular Therapies to $132 From $87, Maintains Neutral Rating MT
31/01/25 Canaccord Genuity Downgrades Intra-Cellular Therapies to Hold From Buy, Adjusts Price Target to $132 From $119 MT
31/01/25 Analysts recommendations: Accenture, Lockheed Martin, Hershey, Tapestry, Occidental Petroleum... Zonebourse
More recommendations

Press Releases: Intra-Cellular Therapies, Inc.

26/02/25 INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI BU
25/02/25 Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results AQ
21/02/25 Intra-Cellular: Q4 Earnings Snapshot AQ
21/02/25 Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results AQ
14/01/25 INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI BU
More press releases

News in other languages: Intra-Cellular Therapies, Inc.

15/04/25 MIDDAY BRIEFING - Unternehmen und Märkte -2-
02/04/25 J&J : acquisition imminente de Intra-Cellular Therapies
01/04/25 Intra Cellular Therapies : Leonteq Securities AG Übernahme/Fusion/Spin off (Sponsored Segment)
20/02/25 Où se situent les sociétés à forte croissance ?
22/01/25 Johnson & Johnson dépasse les attentes au T4 avec ses anticancéreux
More news

Course Extremes

3 years 45.5
Extreme 45.5
 131.98
5 years 28.4
Extreme 28.4
 131.98
10 years 6.75
Extreme 6.75
 131.98
More quotes

Managers and Directors: Intra-Cellular Therapies, Inc.

Manager TitleAgeSince
Willie Earley CTO
 Chief Tech/Sci/R&D Officer - 01/04/2022
Karen Sheehy CMP
 Compliance Officer 64 02/07/2019
Randall Nixon SEC
 Corporate Secretary - -
More insiders

Latest insider transactions

Date Insider Type Main position Quantity % Market Cap.
2/4/25
ALEXANDRIA REAL ESTATE EQUITIES, INC.
Issuer saleCompany 10,000 0.0094%
2/4/25
Joel Marcus
Issuer sale

Director

55,511 0.0522%
2/4/25
Suresh Durgam
Issuer sale

Chief Technology Officer

265,944 0.2501%
Transaction History

Biopharmaceuticals

Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5-day change 1-year change 3-year change Capi.($)
INTRA-CELLULAR THERAPIES, INC. Stock Intra-Cellular Therapies, Inc.
-0.04%-.--%-.--%+125.34% 14.02B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.04%+10.56%+34.48%+0.28% 75.96B
UCB Stock UCB
+2.64%-8.39%+24.13%+188.08% 49.03B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.02%-3.74%-7.47%+21.83% 47.88B
CSL LIMITED Stock CSL Limited
+1.42%+9.32%-50.68%-50.72% 43.39B
BIOGEN INC. Stock Biogen Inc.
-0.87%+0.50%+56.30%-23.16% 30.8B
INCYTE CORPORATION Stock Incyte Corporation
-0.66%-7.80%+53.51%+88.28% 24.45B
MODERNA, INC. Stock Moderna, Inc.
-1.29%+0.81%+103.53%-48.00% 22.75B
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
+4.15%+0.44%-2.80%+175.30% 19.24B
BRIDGEBIO PHARMA, INC. Stock BridgeBio Pharma, Inc.
-0.10%-4.16%+71.71%+162.37% 16.04B
Average +0.93%-0.72%+28.27%+63.96% 34.36B
Weighted average by Cap. +1.18%+0.57%+22.53%+47.08%
See all sector performances

Financials

2023 2024
Net sales 464M 402M 375M 345M 651M 44.16B 658M 4.41B 1.73B 22.09B 1.74B 1.71B 73.17B 681M 590M 550M 506M 954M 64.74B 965M 6.46B 2.54B 32.39B 2.56B 2.5B 107B
Net income -140M -121M -113M -104M -196M -13.28B -198M -1.33B -520M -6.65B -525M -513M -22.01B -74.68M -64.68M -60.29M -55.45M -105M -7.1B -106M -708M -278M -3.55B -280M -274M -11.77B
Net Debt -481M -417M -388M -357M -674M -45.74B -682M -4.56B -1.79B -22.88B -1.81B -1.77B -75.79B -984M -852M -795M -731M -1.38B -93.57B -1.39B -9.34B -3.66B -46.82B -3.7B -3.61B -155B
* Estimated data More financial data

Company Profile

Logo Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs that address underserved medical needs primarily in psychiatric and neurological disorders. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Lumateperone is also being studied for the treatment of major depressive disorder, and other psychiatric and neurological disorders. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as the ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program.
Employees
860
Sector
Pharmaceuticals
More about the company

Income Statement and Estimates

More financial data

Ratings

Trader

Trader

This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

-
Investor

Investor

This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

-
Global

Global

This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.

-
Quality

Quality

This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.

-
ESG MSCI

ESG MSCI

The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.

BBB
More Ratings
  1. Stock Market
  2. Stocks
  3. ITCI Stock

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

MarketScreener
United-States
MarketScreener Canada
Canada

MIDDLE EAST

MarketScreener Saudi Arabia
Saudi Arabia
MarketScreener UAE Emirates
United Arab Emirates

EUROPE

Zonebourse
France
MarketScreener Deutschland
Deutschland
Zonebourse Suisse
Suisse
MarketScreener Schweiz
Schweiz
MarketScreener Italia
Italia
MarketScreener Österreich
Österreich
MarketScreener België
België
MarketScreener Nederland
Nederland
MarketScreener España
España
MarketScreener Sverige
Sverige
MarketScreener UK
United Kingdom

APAC

MarketScreener Australia
Australia
MarketScreener India
India
MarketScreener Hong Kong
Hong Kong